-
Mashup Score: 3FDA Grants Priority Review to New Drug Application for Sunvozertinib in NSCLC | Docwire News - 9 day(s) ago
Read the full article here
Tweet
-
Mashup Score: 1
Read the full article here
Tweet-
🫁 The phase 3 MARIPOSA study has met its final pre-specified secondary endpoint of OS, according to an announcement from Johnson & Johnson today. ➡️ Learn more about the new data and next steps: https://t.co/CSZxxQbpyv #lcsm #NSCLC #EGFR https://t.co/i5eLSjtZL9
-
-
Mashup Score: 1Maintenance Atezolizumab Plus Talazoparib Shows Improvement in Patients with ES-SCLC | Docwire News - 9 day(s) ago
Read the full article here
Tweet-
📰 Maintenance atezolizumab plus talazoparib improved PFS over atezolizumab alone in patients with SLFN11-positive ES-SCLC who did not progress following initial chemoimmunotherapy, according to a study published in @JTOonline. ➡️ Learn more: https://t.co/yJu1LxU41f #SCLC #lcsm https://t.co/7FssZw5pmy
-
-
Mashup Score: 0Study Highlights Importance of Pretreatment Frailty Assessments for Older Adults With Advanced NSCLC | Docwire News - 9 day(s) ago
Read the full article here
Tweet-
📋 Can pretreatment frailty assessments help identify older adults with NSCLC who are at risk for poor outcomes? 💡A study published in @OncJournal by a team from @UCSF provided insights. ➡️ Learn more: https://t.co/2mBUJwokeb #lcsm #LungCancer #NSCLC https://t.co/Y6CpVhFT8F
-
-
Mashup Score: 0FDA Approves Subcutaneous Injection of Nivolumab, Hyaluronidase-nvhy for NSCLC, Other Solid Tumors | Docwire News - 9 day(s) ago
Read the full article here
Tweet-
📰 REGULATORY UPDATE: The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection across most previously approved nivolumab indications for adults with solid tumors, including NSCLC. ➡️ Learn more: https://t.co/ptjgPdbAYn #lcsm #NSCLC #LungCancer https://t.co/s0wpbHocoi
-
-
Mashup Score: 6Phase 2 Study Evaluates Response-Based Adaptive Radiotherapy for NSCLC | Docwire News - 9 day(s) ago
Read the full article here
Tweet-
🫁 Personalized response-based adaptive radiation therapy with concurrent chemotherapy provided "excellent local control" in locally advanced NSCLC, according to a study by a team from @UMichRadOnc. ➡️ Learn more: https://t.co/mWducczLQS #NSCLC #lcsm https://t.co/HPEyG0tZ2p
-
📰 The US FDA has accepted and granted priority review to the New Drug Application for sunvozertinib as a treatment for certain patients with NSCLC. ➡️ Learn more about the NDA and the next steps: https://t.co/c2a5AILRHw #NSCLC #lcsm https://t.co/EIGfz1Vu1d